Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748230 | 0.86 | PPARA (0.48) | APPDYRK1AKMT2ACYP2A6NPSR1 | |
| SCHEMBL8170037 | 0.82 | KMT2A (0.47) | APPDYRK1AKMT2AMAPTKDM4E | |
| SCHEMBL507554 | 0.80 | APP (0.56) | APPDYRK1ACSNK1DCSNK1G2CYP2C9 | |
| SCHEMBL6633096 | 0.79 | DYRK1A (0.56) | APPDYRK1ACSNK1DCSNK1G2KMT2A | |
| SCHEMBL10274766 | 0.79 | APP (0.55) | APPDYRK1ACSNK1DCSNK1G2CYP2C9 | |
| SCHEMBL2032785 | 0.79 | APP (0.55) | APPDYRK1ACSNK1DCSNK1G2CYP2C9 | |
| SCHEMBL2001976 | 0.79 | APP (0.63) | APPDYRK1AKMT2ACYP2C9CYP3A4 | |
| SCHEMBL28327150 | 0.79 | APP (0.55) | APPDYRK1ACSNK1DCSNK1G2CYP2C9 | |
| SCHEMBL24265948 | 0.78 | APP (0.51) | APPDYRK1ACSNK1DCSNK1G2KMT2A | |
| SCHEMBL334252 | 0.77 | NPC1 (0.61) | APPDYRK1AKMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-12-22 | — | — | US | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC | 2004-09-09 | — | — | US | disclosed |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC. | 2003-09-11 | — | — | US | disclosed |
| US-6583157-B2 | Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-0043013-B1 | PROCESS FOR THE PREPARATION OF 2-CHLORO-BENZOTHIAZOLES | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-06-01 | — | — | EP | disclosed |
| EP-0043013-A1 | Process for the preparation of 2-chloro-benzothiazoles | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | APP 2765/4885DYRK1A 2300/4885CSNK1D 433/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | APP 3418/4885DYRK1A 3333/4885CSNK1D 3812/4885 |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | APP 3233/4885DYRK1A 3216/4885CSNK1D 2239/4885 |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | APP 3233/4885DYRK1A 3216/4885CSNK1D 2239/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | APP 3233/4885DYRK1A 3216/4885CSNK1D 2239/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | APP 2556/4885DYRK1A 2592/4885CSNK1D 534/4885 |
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | HNMT, TPH1, TPH2 | APP 1711/4885DYRK1A 1779/4885CSNK1D 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.